AMEXHealth CareMedical DevicesSnapshot 2026-07-23
Reading MYO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround story in the healthcare sector. The current thesis state is cautious, as the company is loss-making and has experienced a decline in momentum.
The market appears to have priced in a low level of fragility, indicating that expectations are somewhat justified. Valuation suggests that MYO is seen as cheap compared to its peers, but there is a significant expectations gap.
Management aims to achieve full-year revenue of $43 million to $46 million, with mixed progress so far. Operating income is improving but remains negative, and there is a near-term risk of missing earnings expectations due to a high probability of misses.
The long-term thesis hinges on the company's ability to maintain revenue guidance and improve operating income. Additionally, the performance of sector bellwethers like ABT, SYK, and MDT will be crucial in determining the overall momentum in the healthcare sector.
In the next 1 to 3 years, MYO's performance will depend on its execution and external sector conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting or exceeding this guidance shows strong demand and supports the full-year target.
Confirms:Q2 revenue reported at $10.3 million or higher.
Disproves:Q2 revenue reported below $10.3 million.
Why it matters: Keeping revenue guidance is important. It helps set expectations and keeps investor confidence high.
Confirms one read:Management says quarterly revenue guidance is the same or better.
Confirms the other:Management cuts its revenue forecast for the quarter.
Why it matters: Good comments on making money could show a change in financial health.
Confirms one read:Management says they plan to make money in the next year.
Confirms the other:Management says there are delays or problems in making money.
Why it matters: Better operating income means the company is managing costs well. It also shows they are working efficiently.
Confirms:Operating income improves from -$3.16 million in Q1 to less negative in Q2.
Disproves:Operating income worsens or stays at -$3.16 million or worse.
Why it matters: If revenue growth speeds up, it could signal a positive shift in the company's performance.
Confirms:Myomo reports revenue growth above 10% year over year.
Disproves:Revenue growth remains below 10% year over year.
Why it matters: More recurring revenue means a stronger business. It also helps keep customers happy.
Confirms:Recurring patient revenue is over 50% of total revenue.
Disproves:Recurring patient revenue is below 50% of total revenue.
Why it matters: Finishing new contracts helps market access. This can increase revenue growth.
Confirms:New in-network payer contracts were announced before Q2 earnings.
Disproves:No new in-network payer contracts announced before Q2 earnings.
Why it matters: Keeping costs low while increasing revenue is important. It helps improve operating income.
Confirms:Operating costs are less than $10 million.
Disproves:Operating costs are more than $10 million.
